Bulevirtide

Bulevirtide is a synthetic 47-amino acid lipopeptide derived from the preS1 domain of the large hepatitis B virus (HBV) surface protein, modified with an N-terminal myristic acid (C13 fatty acid) group. It acts as a competitive entry inhibitor targeting the sodium taurocholate co-transporting polypeptide (NTCP), a hepatocellular bile acid transporter expressed on the sinusoidal surface of hepatocytes that serves as the shared cellular receptor for both HBV and HDV.

Cryo-electron microscopy studies resolved three functional binding domains (Liu et al., Nature Communications, 2024; DOI 10.1038/s41467-024-46706-w): a myristoyl group anchoring the peptide to the outer membrane via transmembrane helices 4 and 5 of NTCP; a globular "plug" segment (residues Gly2–Asp20) that wedges into the bile salt transport tunnel approximately halfway through the membrane bilayer, occluding the substrate-binding pocket; and a C-terminal "string" (residues Pro21–Gly48) that spreads across the extracellular receptor surface and contacts extracellular loop 1. This three-point engagement confers high-affinity, competitive inhibition of viral preS1-NTCP interaction.

Because HDV is an obligate satellite virus requiring HBV-derived envelope proteins (HBsAg) for virion assembly and cell-to-cell spread, blocking NTCP-mediated hepatocyte entry effectively interrupts the entire HDV infectious cycle. As a secondary pharmacodynamic effect, bulevirtide inhibits hepatic taurocholate uptake (IC50 approximately 195 nM), producing the asymptomatic serum bile acid elevations consistently observed in treated patients.

The clinical development of bulevirtide spans four controlled trials. Phase 2 study MYR202 (n=118; dose-ranging at 2, 5, and 10 mg versus no treatment) and Phase 2 MYR203 (n=90; monotherapy and combination arms including pegylated interferon alfa-2a) established proof of concept for dose-dependent HDV RNA reduction, though most patients experienced viral rebound during off-treatment follow-up.

The pivotal Phase 3 MYR301 trial (NCT03852719; n=150, compensated chronic HDV infection) randomized patients to bulevirtide 2 mg/day (n=49), 10 mg/day (n=50), or delayed-treatment control (n=51). At Week 48, combined virological and biochemical response — defined as undetectable HDV RNA or a decrease of at least 2 log10 IU/mL plus ALT normalization — was achieved by 45% in the 2 mg arm and 48% in the 10 mg arm versus 2% in the control group. By Week 144, combined response rates rose to 55% and 57% for the 2 mg and 10 mg arms respectively, with undetectable HDV RNA in 25% (2 mg) and 50% (10 mg) of patients. Post-treatment follow-up showed that 36% of treated patients maintained virological suppression for approximately two years after stopping; patients who achieved undetectable HDV RNA for at least 96 consecutive weeks on therapy had minimal subsequent relapse risk.

Phase 3 MYR204 (n=175) evaluated combinations with PegIFNα: on-treatment undetectable HDV RNA reached 70% in the BLV 10 mg plus PegIFNα arm versus 22% with BLV monotherapy and 21% with PegIFNα alone.

Real-world cohorts reinforce these findings. A German multicenter study (n=114) reported 76% achieving at least 2 log10 HDV RNA decline at a median 38 weeks. The European SAVE-D cohort (n=244, predominantly cirrhotic) showed 79% virological response and 48% undetectable HDV RNA at Week 96. A 2025 network meta-analysis (12 studies, approximately 900 patients) confirmed bulevirtide plus PegIFNα as the most efficacious regimen for on-treatment viral suppression.

These data supported conditional EMA authorization in July 2020 and FDA accelerated approval on May 22, 2026, both based on the surrogate endpoints of HDV RNA suppression and ALT normalization. Continued approval in the United States is contingent on a long-term confirmatory outcomes study.

The FDA-approved dose of bulevirtide (Hepcludex) in the United States is 8.5 mg administered subcutaneously once daily, supplied as a lyophilized powder in single-dose vials. In the European Union, the EMA-authorized dose has been 2 mg subcutaneously once daily since conditional approval in July 2020. The Phase 3 MYR301 trial also evaluated 10 mg/day (administered as two 5 mg injections) to assess dose-response relationships; the higher dose produced greater rates of undetectable HDV RNA at Week 144 (50% vs. 25%) without a substantially different safety profile.

Treatment duration in the pivotal trial extended to 144 weeks. Emerging evidence suggests that longer uninterrupted treatment correlates with higher rates of sustained virological suppression after stopping; no formally validated stopping rule has been established, though European expert guidance indicates discontinuation may be considered in patients achieving durable undetectable HDV RNA for at least 96 weeks on therapy. Re-treatment after discontinuation has not been systematically evaluated.

No dose adjustment is specified for patients with compensated cirrhosis (Child-Pugh A or B). Bulevirtide is not approved for decompensated cirrhosis (Child-Pugh C); use in that setting was excluded from pivotal trials, though small observational cohorts (n=19) have reported partial benefit including improvement from Child-Pugh B to A in 47% of selected patients.

This information is provided for educational purposes only and does not constitute medical advice. Dosing decisions require individualized assessment by a qualified healthcare provider experienced in managing chronic viral hepatitis.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

The most studied combination is bulevirtide plus pegylated interferon alfa-2a (PegIFNα). In the Phase 3 MYR204 trial (n=175), BLV 10 mg plus PegIFNα produced on-treatment undetectable HDV RNA in 70% of patients versus 22% with BLV monotherapy and 21% with PegIFNα alone. Post-treatment undetectable RNA was maintained in 46% with the combination at 48 weeks follow-up. A 2025 network meta-analysis (12 studies, approximately 900 patients) found bulevirtide plus PegIFNα had the highest odds ratio for end-of-treatment undetectable HDV RNA (OR 260.08), though only 18.4% of patients across all regimens maintained suppression beyond 24 weeks post-treatment, underscoring the difficulty of achieving durable off-treatment remission. The trade-off is significant: PegIFNα adds Grade 3/4 adverse events in approximately 51% of patients and is contraindicated in decompensated liver disease and multiple comorbid conditions.

Per prescribing information, all patients receiving bulevirtide should have their underlying HBV infection managed concurrently; in clinical practice and real-world cohorts, virtually all patients also receive an HBV nucleos(t)ide analogue (most commonly tenofovir disoproxil fumarate or entecavir). The incremental benefit of the nucleos(t)ide analogue on HDV outcomes beyond HBV suppression has not been established in randomized comparisons.

Investigational combinations with HBV capsid assembly modulators and RNA interference agents targeting HBsAg are under early-phase evaluation as of 2025–2026; evidence for these strategies remains preliminary and should not be considered established practice.

Bulevirtide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

The integrated safety analysis of trials MYR203, MYR204, and MYR301 (n=269 patients receiving bulevirtide for up to 48 weeks) found the adverse event profile to be predominantly mild to moderate (Grade 1–2).

Reported adverse events versus untreated control included: • Elevated total serum bile acids: 20% (2 mg), 17% (10 mg) vs. 0% control; consistently asymptomatic and reversible after discontinuation. • Injection-site reactions: 16% (2 mg), 20% (10 mg). • Headache: 16–17% across doses. • Pruritus: 10–11%. • Eosinophilia: 4–9%.

Grade 3 or higher adverse events attributable to bulevirtide occurred in 3% (2 mg arm) and 4% (10 mg arm) of patients — markedly lower than the 51% Grade 3/4 rate observed with pegylated interferon alfa monotherapy. No drug-related serious adverse events were recorded in the pivotal trials, and no patients in the integrated analysis discontinued treatment due to bulevirtide-related toxicity.

Hepcludex carries a Boxed Warning for severe acute exacerbations of hepatitis D and hepatitis B following treatment discontinuation. These post-discontinuation flares can be clinically significant, particularly in patients with cirrhosis, who are at heightened risk for hepatic decompensation. Prescribing information requires monitoring of hepatic function, HBV DNA, and HDV RNA for at least six months after stopping bulevirtide.

Post-marketing experience includes reports of hypersensitivity reactions including anaphylaxis. Bulevirtide is not approved for decompensated cirrhosis (Child-Pugh C) and was excluded from pivotal trials. No hepatic decompensation or treatment-related deaths occurred in any controlled trial.